Source link : https://www.newshealth.biz/health-news/a-watershed-moment-glp-1-drug-succeeds-in-late-stage-mash-trial/
Semaglutide (Wegovy) improved liver fibrosis in patients with metabolic dysfunction-associated steatohepatitis (MASH) and led to greater rates of MASH resolution, an interim analysis of a phase III trial showed. In part 1 of the so-called ESSENCE trial, treatment with the GLP-1 receptor agonist resulted in higher week-72 rates of steatohepatitis resolution without worsening of liver […]
Author : News Health
Publish date : 2024-11-20 21:22:02
Copyright for syndicated content belongs to the linked Source.
Categories